Cryptobiotix

Cryptobiotix is a biotechnology research company based in Ghent, Belgium, that specializes in preclinical gastrointestinal and microbiome research. Founded in 2021, the company developed the proprietary ex vivo SIFR technology pipeline, which is designed to bridge the gap between preclinical data and clinical outcomes. This technology simulates the entire gastrointestinal tract, including digestion, gut microbiome fermentation, and host interactions, to provide mechanistic insights into how products interact with the gut. By utilizing high-throughput automation and biorelevant models, Cryptobiotix helps partners in the food, feed, biotech, and pharmaceutical industries characterize product efficacy, optimize dosing, and investigate inter-individual variability in gut responses.

The company’s services enable clients to de-risk clinical trials and support regulatory submissions by generating robust, mechanistic evidence. Cryptobiotix offers various research modules, including screening modes for early candidate evaluation and in-depth prism mode for mechanistic characterization. By providing actionable, data-rich reports that account for human physiological complexity, the firm helps accelerate product development cycles while reducing reliance on animal testing. Their work is supported by a portfolio of peer-reviewed publications and validation studies that demonstrate the predictive capabilities of their SIFR technology across diverse areas such as nutrition, health, and disease management.